▽ Sort by :: Latest

Search articles

Filter

September 2026

Trailing rivals, AbbVie scores win with dual-acting myeloma drug

www.biopharmadive.com· Sep 04·Cell Therapy·Phase 3·CAR T·52

Sep 04

This week in charts: China deals, stock flatlines and Lilly’s M&A spree

Eli Lilly · LLY

www.biopharmadive.com· Sep 04·Gene Therapy·Phase 1·Phase 3·Gene therapy·90

Sep 04

Ionis’ rare neurology drug approved; Pfizer inks an ADC deal

www.biopharmadive.com· Sep 04·Cell Therapy·Phase 1·Phase 2·Phase 3·96

Sep 04

News - Redesigned Landing Sites Lift Bxb1 Integration Efficiency

crisprmedicinenews.com· Sep 04·Gene Editing·CRISPR·Prime editing·62

Sep 04

Ultragenyx to weigh ‘significant’ cost cuts as Angelman drug fails key study

www.biopharmadive.com· Sep 03·Gene Therapy·Phase 3·Gene therapy·54

Sep 03

The hidden scale-out problem behind CAR-T’s growth

www.biopharmadive.com· Sep 03·Cell Therapy·Phase 1·Cell therapy·CAR T·64

Sep 03

Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts

CRISPR Therapeutics · CRSP

www.biopharmadive.com· Sep 02·Gene Editing·CRISPR·Cell therapy·CAR T·84

Sep 02

UniQure, after setbacks, seeks FDA approval of Huntington’s gene therapy

www.biopharmadive.com· Sep 02·Fda Approval·FDA approval·Gene therapy·80

Sep 02

Teva claims success in celiac study; BioMarin, Ascendis settle patent dispute

www.biopharmadive.com· Sep 02·Clinical Trial·Statistically significant·Phase 2·Phase 3·58

Sep 02

August 2026

Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns

www.biopharmadive.com· Aug 31·Cell Therapy·Phase 1·Cell therapy·CAR T·64

Aug 31

StockWatch: Revolution Shares Stay Flat Despite Historic FDA Approval of Oral Pancreatic Cancer Therapy

www.genengnews.com· Aug 30·Fda Approval·FDA approval·NCT06625320·44

Aug 30

CAR T-Cell Therapy Puts Severe Rheumatoid Arthritis Into Remission in First Clinical Trial

www.genengnews.com· Aug 28·Cell Therapy·Cell therapy·CAR T·56

Aug 28

AstraZeneca, Ionis data spark debate about RNA drugs’ impact on deadly heart disease

Novo Nordisk · NVO

www.biopharmadive.com· Aug 28·Clinical Trial·Statistically significant·Pivotal trial·44

Aug 28

News - CMN Weekly (28 August 2026) - Your Weekly CRISPR Medicine News

Vertex Pharmaceuticals · VRTX·CRISPR Therapeutics · CRSP·Intellia Therapeutics · NTLA

crisprmedicinenews.com· Aug 28·Gene Editing·Phase 1·Phase 2·Gene editing·100

Aug 28

New data could widen use of AstraZeneca, Amgen immune disease drug

Amgen · AMGN

www.biopharmadive.com· Aug 27·Fda Approval·Statistically significant·Expanded approval·Phase 3·72

Aug 27

Zepbound may cut healthcare costs, study says; Summit, Akeso drug hits in another China trial

Eli Lilly · LLY

www.biopharmadive.com· Aug 26·Fda Approval·Statistically significant·FDA approval·Phase 2·100

Aug 26

News - UNCOVERseq exposes off-targets missed by established standards

crisprmedicinenews.com· Aug 26·Gene Editing·Gene editing·CRISPR·62

Aug 26

FDA extends review of Capricor cell therapy; Pain drug startup to go public

www.biopharmadive.com· Aug 24·Gene Therapy·Functional cure·Cell therapy·54

Aug 24

Roche commits to lean-mass preservation with Hanmi obesity deal

Eli Lilly · LLY·Novo Nordisk · NVO

www.biopharmadive.com· Aug 24·Peptide·Phase 1·GLP 1·46

Aug 24

News - CARBON Newsletter (21 August 2026) - Your Latest News About CRISPR in AgroBio

crisprmedicinenews.com· Aug 21·Gene Editing·Gene editing·CRISPR·Prime editing·100

Aug 21

Ultragenyx, after setbacks, nabs first gene therapy approval

www.biopharmadive.com· Aug 20·Fda Approval·FDA approval·Pivotal trial·Gene therapy·80

Aug 20

Moderna and Merck cancer vaccine returns ‘landmark’ result in melanoma

www.biopharmadive.com· Aug 19·Clinical Trial·Statistically significant·Phase 2·Phase 3·58

Aug 19

Leo Pharma buys rare skin disease drug in $435M deal

www.biopharmadive.com· Aug 18·Gene Therapy·Phase 3·Gene therapy·54

Aug 18

News - In Vivo CRISPR Medicine: From Scientific Promise to Patients at Scale

crisprmedicinenews.com· Aug 18·Gene Editing·Gene editing·CRISPR·Gene therapy·92

Aug 18

Argenx jumps on Phase 3 data for blockbuster Vyvgart

www.biopharmadive.com· Aug 17·Clinical Trial·Positive data·Phase 3·46

Aug 17

News - Triple Base Editor Diversifies Three Nucleotides at Once

crisprmedicinenews.com· Aug 17·Gene Editing·CRISPR·Base editing·62

Aug 17

Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene

Amgen · AMGN

www.biopharmadive.com· Aug 14·Fda Approval·FDA approval·Phase 3·72

Aug 14

News - Clinical: FDA Accelerates Allogene's TALEN-Edited Lymphoma Cell Therapy

crisprmedicinenews.com· Aug 14·Gene Editing·CRISPR·Cell therapy·60

Aug 14

News - Founder, Jens-Ole Bock, CMN, Keynote Speaker at the CRISPR Gene Editing Hands-on Workshop at University of Lagos, Nigeria

crisprmedicinenews.com· Aug 14·Gene Editing·Gene editing·CRISPR·62

Aug 14

New Taiho, Cullian data heats up lung cancer drug battle

www.biopharmadive.com· Aug 13·Clinical Trial·Statistically significant·Phase 2·Phase 3·58

Aug 13

PTC takes a chance on Sangamo’s Fabry disease gene therapy

Eli Lilly · LLY

www.biopharmadive.com· Aug 13·Fda Approval·FDA approval·Gene therapy·80

Aug 13

Allogeneic CAR T Company Prepares to Widen Access to Patients

www.genengnews.com· Aug 12·Cell Therapy·Cell therapy·CAR T·56

Aug 12

Lilly files six lawsuits in bid to shut down ‘black market’ for retatrutide

Eli Lilly · LLY·Novo Nordisk · NVO

www.biopharmadive.com· Aug 12·Peptide·GLP 1·62

Aug 12

Psychedelics developer Definium scores more positive data for LSD pill

www.biopharmadive.com· Aug 12·Clinical Trial·Positive data·Phase 3·46

Aug 12

News - Clinical: Expanded Access Takes SNIPR001 Beyond the Gut

crisprmedicinenews.com· Aug 12·Gene Editing·Phase 1·CRISPR·46

Aug 12

Sionna cystic fibrosis drug fails key trial, removing threat to Vertex

Vertex Pharmaceuticals · VRTX

www.biopharmadive.com· Aug 10·Clinical Trial·Positive data·Statistically significant·Phase 1·66

Aug 10

Scribe’s Benjamin Oakes on a rare IPO and bringing CRISPR to the masses

Eli Lilly · LLY

www.biopharmadive.com· Aug 10·Gene Editing·Gene editing·CRISPR·Conference·44

Aug 10

News - Base Editing Protects Brains From Mutant Huntingtin

crisprmedicinenews.com· Aug 07·Gene Editing·CRISPR·Base editing·62

Aug 07

Replimune rebounds to win FDA approval of melanoma drug

www.biopharmadive.com· Aug 06·Fda Approval·FDA approval·Phase 3·72

Aug 06

FDA approves Moderna’s mRNA flu vaccine

www.biopharmadive.com· Aug 06·Fda Approval·FDA approval·44

Aug 06

News - Probiotics: Hybrid Vesicles Sharpen CRISPR Attack on Dental Pathogen

crisprmedicinenews.com· Aug 05·Gene Editing·Gene editing·CRISPR·62

Aug 05

J&J pharma leader to retire; Krystal slumps on gene therapy miss

www.biopharmadive.com· Aug 04·Gene Therapy·Phase 2·Phase 3·Gene therapy·50

Aug 04

July 2026

News - AEGIS Targets Personalised Editing for Childhood Immune Disorders

crisprmedicinenews.com· Jul 31·Gene Editing·Gene editing·CRISPR·62

Jul 31

J&J nabs option to buy ‘in vivo’ CAR-T maker Sail for nearly $2.6B

Eli Lilly · LLY

www.biopharmadive.com· Jul 30·Cell Therapy·Cell therapy·CAR T·56

Jul 30

Capricor Duchenne cell therapy voted down by FDA panel

www.biopharmadive.com· Jul 29·Cell Therapy·Phase 3·Cell therapy·50

Jul 29

Base Editing Strategy Alleviates Huntington’s Disease in Mice

www.genengnews.com· Jul 29·Gene Editing·CRISPR·Base editing·62

Jul 29

News - Dual-Vector Editing Maintains Year-Long Function for DMD0

crisprmedicinenews.com· Jul 29·Gene Editing·Orphan drug designation·IND clearance·CRISPR·88

Jul 29

News - Dual-Vector Editing Maintains Year-Long Function for DMD

crisprmedicinenews.com· Jul 29·Gene Editing·Orphan drug designation·IND clearance·CRISPR·88

Jul 29

Argenx to acquire Forte in $2.2B deal for ‘differentiated’ immune drug

www.biopharmadive.com· Jul 27·Fda Approval·Expanded approval·Phase 2·52

Jul 27

FDA scientists question Capricor data; Legend CEO steps down

www.biopharmadive.com· Jul 27·Cell Therapy·Phase 3·Cell therapy·50

Jul 27

Sarepta, in search of a turnaround, taps ex-AbbVie exec Severino as CEO

Amgen · AMGN

www.biopharmadive.com· Jul 27·Gene Editing·Gene editing·Gene therapy·Earnings·42

Jul 27

News - Brain-directed base editing ends in death

crisprmedicinenews.com· Jul 27·Gene Editing·CRISPR·Base editing·Cell therapy·84

Jul 27

News - Brain-directed gene editing ends in death

crisprmedicinenews.com· Jul 27·Gene Editing·Gene editing·CRISPR·Cell therapy·84

Jul 27

News - CMN Weekly (24 Juli 2026) - Your Weekly CRISPR Medicine News

Vertex Pharmaceuticals · VRTX·Beam Therapeutics · BEAM·Eli Lilly · LLY

crisprmedicinenews.com· Jul 24·Fda Approval·First In Human·Expanded approval·Phase 1·100

Jul 24

Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myeloma

Eli Lilly · LLY·Novo Nordisk · NVO

www.biopharmadive.com· Jul 24·Peptide·Phase 3·GLP 1·56

Jul 24

Scribe secures $129M in a rare gene editing IPO

www.biopharmadive.com· Jul 24·Gene Editing·First In Human·Gene editing·48

Jul 24

Lilly, with new data, to seek FDA approval of obesity drug retatrutide

Eli Lilly · LLY·Novo Nordisk · NVO·Amgen · AMGN

www.biopharmadive.com· Jul 23·Fda Approval·FDA approval·Phase 3·GLP 1·100

Jul 23

Agios scraps sickle cell drug

Novo Nordisk · NVO

www.biopharmadive.com· Jul 21·Fda Approval·FDA approval·Phase 3·Cell therapy·94

Jul 21

News - CRISPR, AI and precision medicine converge for children

crisprmedicinenews.com· Jul 20·Gene Editing·CRISPR·Gene therapy·64

Jul 20

Bristol Myers to build ‘powerful’ AI factory; Samsung Biologics bids for peptide maker

Eli Lilly · LLY

www.biopharmadive.com· Jul 20·Peptide·Phase 2·GLP 1·58

Jul 20

Jasper gets a lifeline in merger with immune drugmaker Kira

www.biopharmadive.com· Jul 17·Clinical Trial·Phase 2·Phase 3·42

Jul 17

Arbutus, Sanofi escalate mRNA patent fights; InnoCare’s TYK2 contender advances

www.biopharmadive.com· Jul 17·Clinical Trial·Phase 2·Phase 3·42

Jul 17

GSK shelves cough drug acquired in $2B deal

www.biopharmadive.com· Jul 17·Clinical Trial·Statistically significant·Phase 2·Phase 3·58

Jul 17

How well are AI-discovered drugs faring in the clinic?

www.biopharmadive.com· Jul 17·Clinical Trial·Phase 1·Phase 2·Phase 3·50

Jul 17

News - CARBON Newsletter (17 July 2026) - Your Latest News About CRISPR in AgroBio

crisprmedicinenews.com· Jul 17·Gene Editing·CRISPR·Prime editing·NCT07166263·62

Jul 17

Gene Therapy Partners Aim to Enhance Protein Expression

www.genengnews.com· Jul 17·Gene Therapy·Gene therapy·Peptide·60

Jul 17

Merck ADC, in China study, shows potential to replace chemo in lung cancer

www.biopharmadive.com· Jul 15·Clinical Trial·Statistically significant·Phase 3·44

Jul 15

Braveheart, Attovia join next wave of biotech IPOs

www.biopharmadive.com· Jul 15·Clinical Trial·Phase 1·Phase 2·Phase 3·50

Jul 15

Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill

Novo Nordisk · NVO

www.biopharmadive.com· Jul 14·Peptide·Phase 2·Phase 3·66

Jul 14

Freenome colorectal cancer test data improve on earlier results

www.biopharmadive.com· Jul 13·Fda Approval·FDA approval·44

Jul 13

News - Epicrispr's EPI-321 Reaches Full Enrolment for FSHD

crisprmedicinenews.com· Jul 13·Gene Editing·Statistically significant·First In Human·CRISPR·68

Jul 13

ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership

www.biopharmadive.com· Jul 10·Gene Editing·Statistically significant·First In Human·Phase 2·96

Jul 10

News - FT819 shows first clinical activity in systemic sclerosis

crisprmedicinenews.com· Jul 10·Gene Editing·Phase 1·CRISPR·Cell therapy·68

Jul 10

Prime wins gene editing dispute; Saol claims latest post-Makary FDA reversal

Beam Therapeutics · BEAM

www.biopharmadive.com· Jul 08·Gene Editing·Phase 3·Gene editing·Base editing·100

Jul 08

News - Retargeted Serine Integrases Enable Precise Large-Gene Insertion

crisprmedicinenews.com· Jul 06·Gene Editing·CRISPR·Prime editing·62

Jul 06

Vertex and CRISPR Therapeutics report durable responses for exa-cel gene-editing therapy

Vertex Pharmaceuticals · VRTX·CRISPR Therapeutics · CRSP

fiercebiotech.com· Jul 05·Gene Editing·Sickle cell disease·CRISPR·Gene editing·86

Jul 05

Intellia reports positive Phase 2 CRISPR data in hereditary angioedema

Intellia Therapeutics · NTLA

biopharmadive.com· Jul 03·Gene Editing·Phase 2·Hereditary angioedema·CRISPR·Positive data·82

Jul 03

News - Base Editing Uncovers Vulnerability in WNT-Driven Colorectal Cancer

crisprmedicinenews.com· Jul 03·Gene Editing·CRISPR·Base editing·62

Jul 03

News - Engineered T Cells Attack PD-L1-Bearing Cancer and Immune Cells

crisprmedicinenews.com· Jul 01·Gene Editing·CRISPR·Peptide·62

Jul 01

June 2026

Eli Lilly peptide obesity candidate meets primary endpoint in Phase 3 trial

Eli Lilly · LLY

genengnews.com· Jun 28·Peptide·Phase 3·Obesity·GLP 1·78

Jun 28

News - CMN Weekly (26 June 2026) - Your Weekly CRISPR Medicine News

Intellia Therapeutics · NTLA·Beam Therapeutics · BEAM·Caribou Biosciences · CRBU

crisprmedicinenews.com· Jun 26·Gene Editing·Phase 1·Phase 3·Gene editing·100

Jun 26

News - CRISPR Therapy Moves Into Younger Children

Vertex Pharmaceuticals · VRTX·CRISPR Therapeutics · CRSP

crisprmedicinenews.com· Jun 24·Gene Editing·Phase 3·Gene editing·CRISPR·80

Jun 24

News - Clinical: Beam Advances Base Editing For PKU

Beam Therapeutics · BEAM

crisprmedicinenews.com· Jun 22·Gene Editing·Phase 1·CRISPR·Base editing·70

Jun 22

Novo Nordisk dual agonist peptide shows positive Phase 2 metabolic data

Novo Nordisk · NVO

biopharmadive.com· Jun 21·Peptide·Phase 2·Type 2 diabetes·Dual agonist·72

Jun 21

News - CARBON Newsletter (19 June 2026) - Your Latest News About CRISPR in AgroBio

crisprmedicinenews.com· Jun 19·Gene Editing·Gene editing·CRISPR·Base editing·100

Jun 19

News - Scaling CRISPR-based gene editing through advanced chemoenzymatic ligation

crisprmedicinenews.com· Jun 18·Gene Editing·Gene editing·CRISPR·SiRNA·80

Jun 18

News - Clinical: Single CRISPR Infusion Curbs Hereditary Angioedema Attacks

Intellia Therapeutics · NTLA

crisprmedicinenews.com· Jun 17·Gene Editing·Phase 3·Gene editing·CRISPR·80

Jun 17

News - Clinical: Caribous' Off-The-Shelf Car-T Drives Durable Myeloma Responses

Caribou Biosciences · CRBU

crisprmedicinenews.com· Jun 15·Gene Editing·Complete response·Phase 1·CRISPR·100

Jun 15

Beam wins FDA clearance to begin first-in-human base-editing study

Beam Therapeutics · BEAM

crisprmedicinenews.com· Jun 12·Gene Editing·Phase 1·Base editing·IND clearance·First In Human·75

Jun 12

News - CRISPR-Cas12a2 Targets Mutant Cancer Transcripts for Selective Cell Death

crisprmedicinenews.com· Jun 10·Gene Editing·Statistically significant·CRISPR·54

Jun 10

News - Base Editing Rewrites Embryo Genomes Precisely

crisprmedicinenews.com· Jun 09·Gene Editing·CRISPR·Base editing·62

Jun 09

News - CAR-T With Nine Engineered Edits Shrinks Colorectal Tumours

crisprmedicinenews.com· Jun 03·Gene Editing·Phase 1·CRISPR·Cell therapy·92

Jun 03

May 2026

Vertex Phase 3 pain study meets primary endpoint

Vertex Pharmaceuticals · VRTX

fiercebiotech.com· May 30·Clinical Trial·Phase 3·Acute pain·Met primary endpoint·Positive data·68

May 30

News - Rival Editors Converge on AATD as Data Mount

Beam Therapeutics · BEAM

crisprmedicinenews.com· May 27·Gene Editing·Phase 1·Phase 2·Gene editing·100

May 27

News - AIRNA's RNA Editor Sidesteps DNA in AATD Correction

crisprmedicinenews.com· May 20·Gene Editing·CRISPR·Cell therapy·RNA editing·82

May 20

News - CRISPRMED27, April 19-22. 2027, Copenhagen, Denmark

crisprmedicinenews.com· May 19·Gene Editing·Gene editing·CRISPR·Conference·44

May 19

FDA approves first gene therapy for rare pediatric disorder

genengnews.com· May 18·Fda Approval·Rare pediatric disorder·FDA approval·Gene therapy·Rare disease·88

May 18

News - FT819 Remodels Lupus B Cells in Clinical Trial

crisprmedicinenews.com· May 13·Gene Editing·Phase 1·CRISPR·Cell therapy·68

May 13

News - Aldevron Joins EGMEDC to Turn Genomic Promise Into European Practice

crisprmedicinenews.com· May 06·Gene Editing·Gene editing·CRISPR·Cell therapy·84

May 06

April 2026

News - Intellia Files BLA After Lonvo-z Meets Phase 3 Endpoints

Intellia Therapeutics · NTLA

crisprmedicinenews.com· Apr 29·Gene Editing·Functional cure·Orphan drug designation·Phase 1·100

Apr 29